FDA Project Orbis Reshapes CMC Submission Strategy for Global Oncology Drug Manufacturers

Concurrent regulatory review under Project Orbis is compressing the submission windows oncology manufacturers once used to sequence CMC documentation across jurisdictions, and the FDA Oncology Center of Excellence is signaling that this parallel-review model is now a structural feature of global oncology development, not an exception.

Launched by the FDA Oncology Center of Excellence (OCE) in May 2019, Project Orbis established a framework for simultaneous submission and review of oncology marketing applications among international regulatory partners. The program was designed to reduce the lag between FDA approval and patient access in countries where regulatory submissions have historically followed, rather than accompanied, US filings. Since inception, the program has processed numerous oncology marketing applications and generated approvals across multiple participating jurisdictions.

For regulatory affairs leads and CMC teams, the operational consequence is direct: a submission package prepared for concurrent review must satisfy the documentation standards of multiple agencies simultaneously. Pivotal oncology trials are increasingly conducted across international sites, and Project Orbis is built on the premise that those global data sets should support coordinated, not sequential, regulatory decisions. Manufacturers that continue to treat ex-US submissions as downstream activities risk misalignment on clinical data cut-offs, labeling negotiations, and manufacturing site assessments running in parallel.

The OCE team leading the program includes R. Angelo de Claro, Acting Associate Director for Global Clinical Sciences, who directs Project Orbis alongside his role as Division Director for Hematologic Malignancies I within CDER's Office of Oncologic Diseases. Dianne Spillman, Associate Director for Global Regulatory Outreach, was instrumental in executing the first collaborative review between Australia, Canada, and the US under the program. Lauren Tesh Hotaki, Senior Health Scientist, currently manages application workflows with foreign regulatory counterparts and supports advisory committee planning. The team structure reflects OCE's intent to sustain the program as a standing operational function rather than a pilot.

For QA directors, the inspection-readiness dimension is worth tracking: concurrent review means manufacturing site data, process validation packages, and quality system documentation may be evaluated by multiple agencies within overlapping timeframes. A gap that surfaces during one agency's review is unlikely to remain invisible to the others.

The Project Orbis approval report, maintained by OCE, provides the most current record of applications processed and approvals issued under the program, a reference point for benchmarking submission timelines against peer products moving through the same concurrent pathway.

Source: FDA Oncology Center of Excellence via FDA.gov (What's New: Drugs RSS Feed), published 14 May 2026.